O

Ocular Therapeutix

Hydrogel-based ocular drug delivery platform

Pharmaceutical Development Contract

Bioprocess & BiomanufacturingPosted on Nov 10
Full-timeBedford, MA, USA$25 /hr

About the Job

Requirements

  • A BS or MS in Chemical Engineering, Bioengineering, Mechanical Engineering, or a related field is required.
  • Wet lab experience is required.
  • Ability to work with people of various educational backgrounds is required.
  • Proficiency in Microsoft Word and Excel is required.
  • Ability to get to the office in Bedford, Massachusetts is required.
  • The role requires mobility and some physical ability to set up and work with equipment.

Responsibilities

  • Assist in designing and executing formulation and process development studies using the company's proprietary PEG technology.
  • Help characterize drug product dimensions, mass, drug load, and morphology.
  • Work with project teams to develop and implement novel test methods.
  • Evaluate and identify process bottlenecks and inefficiencies and propose solutions.
  • Design and 3D print custom fixtures to improve a manufacturing process.
  • Maintain inventory and order general lab supplies, chemicals, and equipment parts.
  • Maintain a laboratory notebook for lab studies.
  • Analyze, summarize, and present data in Pharmaceutical Development team meetings.

About the Company

Ocular Therapeutix

Hydrogel-based ocular drug delivery platform

Ocular Therapeutix develops and commercializes eye therapies using a hydrogel-based drug-delivery platform. Its approach uses a biodegradable hydrogel that stays in the eye to release medicine over time, reducing the need for frequent eye drops or injections. The flagship product, DEXTENZA, is a corticosteroid insert placed by a physician after eye surgery to treat inflammation and pain, providing sustained local treatment. The company differentiates itself by offering a scalable platform that can be used to create a range of eye medications and devices for conditions such as glaucoma, retinal diseases (including wet AMD), and dry eye, rather than competing solely on one drug. Revenue comes from selling these products to physicians and surgical centers. The goal is to expand the hydrogel delivery platform into a broader pipeline of eye therapies to improve patient outcomes and adherence by delivering drugs where and when they are needed most.

Company size
201-500
Company stage
IPO
Headquarters
Bedford, MA
Founded
2006

Recently Posted Jobs

Explore more opportunities at Ocular Therapeutix

See more jobs